Literature DB >> 21773989

A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone.

Hong Chen1, Linda C Gilbert, X Lu, Zhaofan Liu, Shaojin You, M Neale Weitzmann, Mark S Nanes, John Adams.   

Abstract

The heterogeneous nuclear ribonucleoprotein (hnRNP)-like estrogen response element-binding protein (ERE-BP) competes with estrogen receptor α (ERα) for occupancy of estrogen response elements (EREs). Here we report that ERE-BP potently stimulates osteoclastogenesis. ERE-BP mRNA and protein were found to be expressed ubiquitously in bone. Overexpression of ERE-BP in cultured osteoblasts stimulated expression of the receptor activator of NF-κB ligand (RANKL) and decreased osteoprotegerin (OPG). The effect of ERE-BP on RANKL was shown to be transcriptional in transient transfection assay and competed with via the ER. Constitutive expression of ERE-BP increased the sensitivity of cells toward 1,25-dihydroxyvitamin D(3) stimulation of RANKL expression. In contrast, knockdown of ERE-BP in stromal ST-2 cells decreased basal RANKL promoter activity. Cocultures of ERE-BP lentivirus-transduced ST-2 cells with spleen monocytes induced formation of multinucleated osteoclasts (OCs) characterized by tartrate-resistant acid phosphatase, calcitonin receptors, and functional calcium resorption from bone slices. Although ERα competed with ERE-BP for an ERE in a dose-dependent manner, ERE-BP was an independent and potent regulator of RANKL and osteoclastogenesis. In preosteoclastic RAW cells, overexpression of ERE-BP increased RANK, upregulated NF-κB signaling, and enhanced differentiation toward a mature OC phenotype independent of RANKL. These results identify ERE-BP as a potent modulator of osteoclastogenesis. We hypothesize that ERE-BP may play a critical role in the regulation of bone homeostasis as a modulator of estrogen sensitivity as well as by direct action on the transcription of critical osteoclastogenic genes.
Copyright © 2011 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773989      PMCID: PMC3417837          DOI: 10.1002/jbmr.456

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  52 in total

1.  RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.

Authors:  Xiaojun Wu; George Pan; Margaret A McKenna; Majd Zayzafoon; Wen-Cheng Xiong; Jay M McDonald
Journal:  J Bone Miner Res       Date:  2004-10-25       Impact factor: 6.741

2.  Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.

Authors:  J P Bilezikian; A Morishima; J Bell; M M Grumbach
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

3.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

Authors:  S K Lee; J A Lorenzo
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

4.  Decrease in the number and apoptosis of alveolar bone osteoclasts in estrogen-treated rats.

Authors:  A P S Faloni; E Sasso-Cerri; E Katchburian; P S Cerri
Journal:  J Periodontal Res       Date:  2007-06       Impact factor: 4.419

5.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

6.  Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Peter V Hauschka; Jason S Carroll; Timothy F Lane; Leonard P Freedman; Myles Brown
Journal:  EMBO J       Date:  2008-01-24       Impact factor: 11.598

7.  Skeletal alterations in ovariectomized rats.

Authors:  T J Wronski; P L Lowry; C C Walsh; L A Ignaszewski
Journal:  Calcif Tissue Int       Date:  1985-05       Impact factor: 4.333

8.  Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6.

Authors:  Lisa J Robinson; Beatrice B Yaroslavskiy; Reed D Griswold; Eva V Zadorozny; Lida Guo; Irina L Tourkova; Harry C Blair
Journal:  Exp Cell Res       Date:  2009-01-30       Impact factor: 3.905

9.  JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.

Authors:  Fumiyo Ikeda; Takuma Matsubara; Taro Tsurukai; Kenji Hata; Riko Nishimura; Toshiyuki Yoneda
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

10.  Fas receptor is required for estrogen deficiency-induced bone loss in mice.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Vladimir Grubisic; Karlo Mihovilovic; Hrvoje Cvija; Peter Ian Croucher; Ana Marusic
Journal:  Lab Invest       Date:  2010-01-18       Impact factor: 5.662

View more
  7 in total

1.  The Effects of Dietary Supplements of Calcium, Vitamin D and Estrogen Hormone on Serum Levels of OPG and RANKL Cytokines and their Relationship with Increased Bone Density in Rats.

Authors:  Fatemeh Piri; Afra Khosravi; Ardeshir Moayeri; Ayat Moradipour; Siamak Derakhshan
Journal:  J Clin Diagn Res       Date:  2016-09-01

Review 2.  Nuclear receptors in osteoclasts.

Authors:  Seyeon Bae; Steven Zeng; Kyung-Hyun Park-Min
Journal:  Curr Opin Pharmacol       Date:  2020-06-20       Impact factor: 5.547

Review 3.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

4.  The protocol for the isolation and cryopreservation of osteoclast precursors from mouse bone marrow and spleen.

Authors:  Iris Boraschi-Diaz; Svetlana V Komarova
Journal:  Cytotechnology       Date:  2014-09-23       Impact factor: 2.058

Review 5.  Bone health and associated metabolic complications in neuromuscular diseases.

Authors:  Nanette C Joyce; Lauren P Hache; Paula R Clemens
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-10-17       Impact factor: 1.784

6.  Evaluation of Hormonal Influence in Patients with Fractures Attributed to Osteoporosis.

Authors:  Danila Malheiros-Souza; Leonardo Franco Pinheiro Gaia; Fausto Fernandes de Almeida Sousa; Pedro Ivo Ferreira Favaro; Virmondes Rodrigues; Denise Bertulucci Rocha Rodrigues
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2021-08-27

7.  Production and Functional Characterization of Murine Osteoclasts Differentiated from ER-Hoxb8-Immortalized Myeloid Progenitor Cells.

Authors:  Frank Zach; Alexandra Mueller; André Gessner
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.